KUALA LUMPUR, June 19 (Bernama) -- Shinkowa Pharmaceutical Co Ltd has acquired all shares of Hakushindo Pharmaceutical Co Ltd -- an organisation that provides research funds to the Project Research Center For Clinical Trials and Preventative Medicine at the Hiroshima University Graduate School of Biomedical & Health Sciences.
Hakushindo Pharmaceutical has carried out the world's first clinical study of the long-term oral intake (24 weeks) of nicotinamide mononucleotide (NMN) by observing the growing hormone, mitochondrial activity and assessed Sirtuin gene expression.
Based on the results of clinical studies at the university, Shinkowa Pharmaceutical, headquartered in Tokyo, Japan intends to develop products based on the newly discovered effects of NMN and to continue clinical research in fields where potential effect is demonstrated, a statement said.
The company will also further build the database of clinical trial results of the project research and intend to actively disclose the information free of charge to researchers and organisations involved in the NMN research.
In September 2015, Shinkowa Pharmaceutical commissioned private clinical trial contractor DRC Co Ltd to implement the world's first human clinical trial of NMN whereby the trial has been completed and the clinical results received.
Currently, the company is procuring NMN from a manufacturer as they have signed a technology licensing agreement regarding NMN manufacturing, aiming to establish and start operating the second NMN manufacturing facility in Japan by the end of this year.
It also has begin preparations to increase capital through a third-party share allocation. The funds will be used for capital investments for NMN manufacturing facility and to carry out clinical trials to request the examination of several patents that they have filed.
Shinkowa Pharmaceutical ia striving to achieve rejuvenation with health food. The company has listed their business in the Singapore Exchange and registering it with CapBridge. More information at shinkowapharma.com.
-- BERNAMA
Hakushindo Pharmaceutical has carried out the world's first clinical study of the long-term oral intake (24 weeks) of nicotinamide mononucleotide (NMN) by observing the growing hormone, mitochondrial activity and assessed Sirtuin gene expression.
Based on the results of clinical studies at the university, Shinkowa Pharmaceutical, headquartered in Tokyo, Japan intends to develop products based on the newly discovered effects of NMN and to continue clinical research in fields where potential effect is demonstrated, a statement said.
The company will also further build the database of clinical trial results of the project research and intend to actively disclose the information free of charge to researchers and organisations involved in the NMN research.
In September 2015, Shinkowa Pharmaceutical commissioned private clinical trial contractor DRC Co Ltd to implement the world's first human clinical trial of NMN whereby the trial has been completed and the clinical results received.
Currently, the company is procuring NMN from a manufacturer as they have signed a technology licensing agreement regarding NMN manufacturing, aiming to establish and start operating the second NMN manufacturing facility in Japan by the end of this year.
It also has begin preparations to increase capital through a third-party share allocation. The funds will be used for capital investments for NMN manufacturing facility and to carry out clinical trials to request the examination of several patents that they have filed.
Shinkowa Pharmaceutical ia striving to achieve rejuvenation with health food. The company has listed their business in the Singapore Exchange and registering it with CapBridge. More information at shinkowapharma.com.
-- BERNAMA
No comments:
Post a Comment